The Medicines Company Infectious Disease Care Group is Drug Discovery in United States that focus on resistant organisms business. They cover business area such as developer, medicinal product, bacterial infection, resistant organism, trademark product, Vabomere, ™, Orbactiv®, Minocin IV, urinary tract infection, gram-positive bacteria, Disease Control, Prevention.
-
Resistant Organisms
-
Parsippany, NJ
United States
Private
developermedicinal productbacterial infectionresistant organismtrademark productVabomere™Orbactiv®Minocin IVurinary tract infectiongram-positive bacteriaDisease ControlPrevention
* We use standard office opening hours in near The Medicines Company Infectious Disease Care Group's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
The Medicines Company Infectious Disease Care Group is Drug Discovery business from United States that founded in - ( years old in ), The Medicines Company Infectious Disease Care Group business is focusing on Resistant Organisms.
The Medicines Company Infectious Disease Care Group headquarter office and corporate office address is located in Parsippany, NJ United States.
The Medicines Company Infectious Disease Care Group was founded in United States.
In , The Medicines Company Infectious Disease Care Group is currently focus on resistant organisms sector.
Above is snippet of Google Trends for "resistant organisms" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with The Medicines Company Infectious Disease Care Group, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
